Core Viewpoint - The company, He Yu-B (02256), has seen a significant stock price increase following the approval of its IND application for the oral PD-L1 inhibitor ABSK043 in combination with the KRAS G12C inhibitor, Goreserib, for treating KRAS G12C mutated NSCLC in China, and its inclusion in the MSCI Global Small Cap Index [1] Group 1: Clinical Development - The IND application for the oral PD-L1 inhibitor ABSK043 in combination with Goreserib has been approved in China, allowing it to enter Phase II clinical trials [1] - The combination therapy targets KRAS G12C mutations in non-small cell lung cancer (NSCLC) [1] Group 2: Market Impact - The stock price of He Yu-B rose over 6% in early trading, with a current increase of 4.92%, reaching HKD 17.93, with a trading volume of HKD 39.0714 million [1] - Inclusion in the MSCI Global Small Cap Index is expected to enhance the company's global visibility and potentially improve liquidity [1] Group 3: Analyst Insights - CICC's report highlights ABSK043 as a promising oral small molecule PD-L1 inhibitor with global potential [1] - The oral + oral combination therapy is anticipated to offer better patient compliance and safety profile compared to injection + oral combinations, warranting attention on future clinical developments [1]
和誉-B早盘涨超6% ABSK043联用戈来雷塞进入二期临床